Grundmark相关文献与解析，生知库 | 链接生命科学的每一步

Sex Differences in Reported Adverse Drug Reactions to COVID-19 Drugs in a Global Database of Individual Case Safety Reports

全球个案安全报告数据库中报告的COVID-19药物不良反应的性别差异

期刊:Drug Safety

影响因子:3.8

doi:10.1007/s40264-020-01000-8

Zekarias, Alem; Watson, Sarah; Vidlin, Sara Hedfors; Grundmark, Birgitta

发表日期：2020

文献求助收藏

Safety Concerns Reported by Patients Identified in a Collaborative Signal Detection Workshop using VigiBase: Results and Reflections from Lareb and Uppsala Monitoring Centre

利用VigiBase开展的协作信号检测研讨会中，患者报告的安全问题：来自Lareb和乌普萨拉监测中心的成果与反思

期刊:Drug Safety

影响因子:3.8

doi:10.1007/s40264-017-0594-2

Watson, Sarah; Chandler, Rebecca E; Taavola, Henric; Härmark, Linda; Grundmark, Birgitta; Zekarias, Alem; Star, Kristina; van Hunsel, Florence

信号转导

发表日期：2018

文献求助收藏

Prospective study of Type 2 diabetes mellitus, anti-diabetic drugs and risk of prostate cancer

2型糖尿病、抗糖尿病药物与前列腺癌风险的前瞻性研究

期刊:International Journal of Cancer

影响因子:4.7

doi:10.1002/ijc.30480

Häggström, Christel; Van Hemelrijck, Mieke; Zethelius, Björn; Robinson, David; Grundmark, Birgitta; Holmberg, Lars; Gudbjörnsdottir, Soffia; Garmo, Hans; Stattin, Pär

Reducing the noise in signal detection of adverse drug reactions by standardizing the background: a pilot study on analyses of proportional reporting ratios-by-therapeutic area

通过标准化背景来降低药物不良反应信号检测中的噪声：按治疗领域划分的比例报告比率分析的试点研究

期刊:European Journal of Clinical Pharmacology

影响因子:2.7

doi:10.1007/s00228-014-1658-1

Grundmark, Birgitta; Holmberg, Lars; Garmo, Hans; Zethelius, Björn

信号转导

发表日期：2014

文献求助收藏

The metabolic syndrome and the risk of prostate cancer under competing risks of death from other causes

代谢综合征与前列腺癌风险，以及其他原因导致的死亡风险并存的情况

期刊:Cancer Epidemiology Biomarkers & Prevention

影响因子:3.4

doi:10.1158/1055-9965.EPI-10-0112

Grundmark, Birgitta; Garmo, Hans; Loda, Massimo; Busch, Christer; Holmberg, Lars; Zethelius, Björn

Remdesivir in the COVID-19 Pandemic: An Analysis of Spontaneous Reports in VigiBase During 2020

瑞德西韦在新冠肺炎疫情中的应用：2020 年 VigiBase 自发报告分析

Sex Differences in Reported Adverse Drug Reactions to COVID-19 Drugs in a Global Database of Individual Case Safety Reports

全球个案安全报告数据库中报告的COVID-19药物不良反应的性别差异

Safety Concerns Reported by Patients Identified in a Collaborative Signal Detection Workshop using VigiBase: Results and Reflections from Lareb and Uppsala Monitoring Centre

利用VigiBase开展的协作信号检测研讨会中，患者报告的安全问题：来自Lareb和乌普萨拉监测中心的成果与反思

Prospective study of Type 2 diabetes mellitus, anti-diabetic drugs and risk of prostate cancer

2型糖尿病、抗糖尿病药物与前列腺癌风险的前瞻性研究

Reducing the noise in signal detection of adverse drug reactions by standardizing the background: a pilot study on analyses of proportional reporting ratios-by-therapeutic area

通过标准化背景来降低药物不良反应信号检测中的噪声：按治疗领域划分的比例报告比率分析的试点研究

The metabolic syndrome and the risk of prostate cancer under competing risks of death from other causes

代谢综合征与前列腺癌风险，以及其他原因导致的死亡风险并存的情况